Terms: = Brain cancer AND FGFR4, CD334, 2264, ENSG00000160867, P22455, MGC20292, TKF, JTK2 AND Treatment
11 results:
1. Design, synthesis, and biological evaluation of 1,6-naphthyridine-2-one derivatives as novel fgfr4 inhibitors for the treatment of colorectal cancer.
Fang B; Lai Y; Yan H; Ma Y; Ni Z; Zhu Q; Zhang J; Ye Y; Wang M; Wang P; Wang Y; Zhang S; Hui M; Wang D; Zhao Y; Li X; Wang K; Liu Z
Eur J Med Chem; 2023 Nov; 259():115703. PubMed ID: 37556948
[TBL] [Abstract] [Full Text] [Related]
2. Anti-cancer effects of 3,4-dihydropyrimido[4,5-d]pyrimidin-2(1H)-one derivatives on hepatocellular carcinoma harboring fgfr4 activation.
Nam Y; Shin I; Kim Y; Ryu S; Kim N; Ju E; Sim T
Neoplasia; 2022 Jan; 24(1):34-49. PubMed ID: 34864570
[TBL] [Abstract] [Full Text] [Related]
3. fgfr4 regulates tumor subtype differentiation in luminal breast cancer and metastatic disease.
Garcia-Recio S; Thennavan A; East MP; Parker JS; Cejalvo JM; Garay JP; Hollern DP; He X; Mott KR; Galván P; Fan C; Selitsky SR; Coffey AR; Marron D; Brasó-Maristany F; Burgués O; Albanell J; Rojo F; Lluch A; de Dueñas EM; Rosen JM; Johnson GL; Carey LA; Prat A; Perou CM
J Clin Invest; 2020 Sep; 130(9):4871-4887. PubMed ID: 32573490
[TBL] [Abstract] [Full Text] [Related]
4. Age and pre quit-day attrition during smoking cessation treatment.
Conroy HE; Jacquart J; Baird SO; Rosenfield D; Davis ML; Powers MB; Frierson GM; Marcus BH; Otto MW; Zvolensky MJ; Smits JAJ
Cogn Behav Ther; 2020 Sep; 49(5):361-373. PubMed ID: 32343190
[TBL] [Abstract] [Full Text] [Related]
5. P-glycoprotein (ABCB1/MDR1) limits brain accumulation and Cytochrome P450-3A (CYP3A) restricts oral availability of the novel fgfr4 inhibitor fisogatinib (BLU-554).
Li W; Sparidans R; El-Lari M; Wang Y; Lebre MC; Beijnen JH; Schinkel AH
Int J Pharm; 2020 Jan; 573():118842. PubMed ID: 31759109
[TBL] [Abstract] [Full Text] [Related]
6. Endoscopic endonasal transsphenoidal approach to large and giant pituitary adenomas: institutional experience and predictors of extent of resection.
Juraschka K; Khan OH; Godoy BL; Monsalves E; Kilian A; Krischek B; Ghare A; Vescan A; Gentili F; Zadeh G
J Neurosurg; 2014 Jul; 121(1):75-83. PubMed ID: 24785323
[TBL] [Abstract] [Full Text] [Related]
7. The fgfr4-G388R polymorphism promotes mitochondrial STAT3 serine phosphorylation to facilitate pituitary growth hormone cell tumorigenesis.
Tateno T; Asa SL; Zheng L; Mayr T; Ullrich A; Ezzat S
PLoS Genet; 2011 Dec; 7(12):e1002400. PubMed ID: 22174695
[TBL] [Abstract] [Full Text] [Related]
8. Targeting N-cadherin through fibroblast growth factor receptor-4: distinct pathogenetic and therapeutic implications.
Ezzat S; Zheng L; Winer D; Asa SL
Mol Endocrinol; 2006 Nov; 20(11):2965-75. PubMed ID: 16857743
[TBL] [Abstract] [Full Text] [Related]
9. treatment of medulloblastoma with postoperative chemotherapy alone: an SFOP prospective trial in young children.
Grill J; Sainte-Rose C; Jouvet A; Gentet JC; Lejars O; Frappaz D; Doz F; Rialland X; Pichon F; Bertozzi AI; Chastagner P; Couanet D; Habrand JL; Raquin MA; Le Deley MC; Kalifa C;
Lancet Oncol; 2005 Aug; 6(8):573-80. PubMed ID: 16054568
[TBL] [Abstract] [Full Text] [Related]
10. Pituitary tumor-derived fibroblast growth factor receptor 4 isoform disrupts neural cell-adhesion molecule/N-cadherin signaling to diminish cell adhesiveness: a mechanism underlying pituitary neoplasia.
Ezzat S; Zheng L; Asa SL
Mol Endocrinol; 2004 Oct; 18(10):2543-52. PubMed ID: 15231874
[TBL] [Abstract] [Full Text] [Related]
11. Growth hormone secretion elicited by GHRH, GHRP-6 or GHRH plus GHRP-6 in patients with microprolactinoma and macroprolactinoma before and after bromocriptine therapy.
Popovic V; Simic M; Ilic L; Micic D; Damjanovic S; Djurovic M; Obradovic S; Dieguez C; Casanueva F
Clin Endocrinol (Oxf); 1998 Jan; 48(1):103-8. PubMed ID: 9509075
[TBL] [Abstract] [Full Text] [Related]
